Signatur Biosciences logo

Signatur Biosciences

Emerging

Simple PCR-based cancer diagnostics running on standard lab equipment to democratize complex disease detection; $7M raised May 2025 from YC S22 competing with Grail and Exact Sciences for accessible liquid biopsy.

45
AI Score
Grade C↑ Trending
AI Visibility Score (Beta)
HealthcareWebsiteUpdated March 2026

Company Overview

About Signatur Biosciences

Signatur Biosciences is a London-based diagnostics company developing simple PCR-based tests that can detect complex diseases like breast cancer and other conditions using standard qPCR machines already present in most clinical laboratories — making sophisticated molecular diagnostics as accessible and operationally simple as a COVID-19 PCR test. Founded in 2022 and a Y Combinator S22 graduate, Signatur raised $7 million in May 2025 to scale its affordable, point-of-care compatible diagnostic solutions that address critical accessibility gaps in cancer diagnostics.

Business Model & Competitive Advantage

Signatur's smart PCR kit approach addresses a fundamental barrier in precision diagnostics: the most sensitive cancer detection tests (liquid biopsy, next-generation sequencing) require specialized expensive equipment and expert bioinformatics analysis that limits their use to major cancer centers. Signatur's tests use standard qPCR machines (which exist in regional hospitals, clinical labs, and diagnostic centers worldwide) and proprietary assay design that extracts equivalent diagnostic information from simpler equipment — democratizing access to early cancer detection beyond specialized oncology centers.

Competitive Landscape 2025–2026

In 2025, Signatur Biosciences competes in the molecular diagnostics and liquid biopsy market with Exact Sciences (Cologuard, Nasdaq: EXAS), Grail (Galleri multi-cancer early detection, Illumina), Foundation Medicine (Roche), and Guardant Health (GUARD) for cancer early detection and molecular diagnostics. The liquid biopsy and multi-cancer early detection space has attracted significant investment — Grail's Galleri test (which screens for 50+ cancers from a blood draw) represents the aspiration of the field but requires specialized sequencing infrastructure at $949 per test. Signatur's PCR-based approach could achieve widespread adoption if it delivers comparable clinical sensitivity on accessible equipment. The $7M May 2025 raise provides the runway to complete clinical validation studies. The 2025 strategy focuses on breast cancer as the lead indication, building the clinical evidence base for regulatory submission, and establishing NHS and international diagnostic laboratory partnerships.

Founded
2022
Curated content • Fact-checked and verified

Recent Activity

View all →

Key Differentiators

Emerging Innovator

Signatur Biosciences is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

45
↑ Trending

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Browser Use logo

Browser Use

Developer Tools
B2bDeveloper ToolsPlatformSaasStartup

Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom

Oracle Health logo

Oracle Health

Healthcare
HealthtechNorth AmericaB2b

Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve

athenahealth logo

athenahealth

Healthcare
B2bCloud NativeEnterpriseErpHealthtechNorth AmericaSaas

athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on

CoverMyMeds logo

CoverMyMeds

Healthcare Revenue Cycle & Health IT
HealthtechB2bPlatformEnterpriseServicesTechnologyAutomationAnalytics

CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline t

Veeva Systems logo

Veeva Systems

Healthcare Tech
B2bHealthtechSaasPublic

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv

Idexx Laboratories logo

Idexx Laboratories

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu

For Signatur Biosciences

Claim This Profile

Are you from Signatur Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Signatur Biosciences Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Signatur Biosciences vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →